[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"brand-hutchmed":3},{"head":4,"company":37,"invest":42,"children":43,"shops":44,"category":45,"sameIndustry":5,"rid":6},{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"brandId":6,"brandLogo":7,"brandImage":5,"brandName":8,"webName":9,"balias":5,"enterId":10,"mainindustry":11,"industry":5,"brandType":12,"brandHonor":5,"brandTel":13,"establishdate":5,"brandBirth":14,"cityarea":5,"brandWebsite":5,"brandSobp":5,"brandVisit":5,"totalVisits":15,"status":16,"isDeleted":16,"comment":5,"remark":5,"logoExistStatus":17,"imageExistStatus":17,"industryId":5,"industryRanking":5,"score":5,"enterName":18,"mallShopList":19,"brandSummary":5,"likes":5,"unlikes":5,"follow":5,"pagetitle":20,"pagekeywords":21,"pagedesc":22,"brandContent":23,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":25,"enterType":26,"enterLegalperson":27,"enterStablishdate":28,"regauthority":29,"licenseValidity":30,"approvaldate":31,"regcapital":32,"incapital":32,"businessscope":33,"ownBrand":5,"enterTelphone":13,"enterWebsite":34,"business":35,"enterQq":5,"enterMail":36,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"regtrademark":5},null,"90325","\u002Fprofile\u002Fupload\u002F2025\u002F01\u002F25\u002F602a527c355aac400827f4226215532d.gif","HUTCHMED","hutchmed",88934,10006,3,"021-20673000","香港",436,0,"1","和记黄埔医药（上海）有限公司",[],"HUTCHMED简介-和黄医药生物科技-品牌之家","HUTCHMED品牌介绍,和黄医药生物科技好不好,和黄医药怎么样,和黄医药,和记黄埔医药(上海)有限公司","HUTCHMED品牌简介，品牌之家为你介绍和记黄埔医药(上海)有限公司旗下HUTCHMED品牌信息，包括品牌介绍、联系方式、主营产品、最新评论、点赞数量等，告诉你和黄医药生物科技怎么样，致力于帮助你了解HUTCHMED真实有效的品牌相关信息。","面相全球市场的创新型生物医药公司，专注于研究、发现、开发及商业化治疗癌症及免疫性疾病靶向治疗及免疫疗法，创造差异化的创新疗法，建立了从发现到开发、从生产到商业化的高度一体化的肿瘤业务\n\n和黄医药是中国较早专注于全球市场的创新型医药研发企业。在过去的20年里，公司建立了具有世界一流的发现和开发能力的全面整合的研发创新平台，现有13种临床阶段的创新抗癌药物正在全球开展临床研究，其中的12种药物由公司自主研发。自成立以来，和黄医药在全球范围内已有13个自主发现的抗肿瘤候选药物进入临床研究阶段，其中首三个创新肿瘤药物现已获批上市——爱优特®（呋喹替尼胶囊）、苏泰达®（索凡替尼胶囊）和沃瑞沙®（赛沃替尼片）。\n\n公司还在中国市场建立了深入的具盈利的商业平台，在中国生产、营销及经销自主研发的创新肿瘤药物，以及处方药和消费保健产品。\n\n和黄医药于纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市（纳斯达克\u002F伦敦证交所：HCM；香港交易所：13）。\n\n公司的核心研发理念是利用多种形式及机制，对癌症及免疫性疾病等复杂疾病进行综合治疗。\n\n公司寻找并发现具有高度选择性、较低的脱靶毒性以及较少药物间相互作用的创新分子，并对其进行临床开发。尤其是对于患有具多种生物学异常的疾病，并因此需要同时使用多种药物治疗的患者来说，这些具有上述特征的创新药物可能带来更多获益。\n\n公司和公司的合资企业每年约生产和销售约47亿剂药物。公司在苏州拥有符合GMP认证的制剂生产工厂，负责公司创新肿瘤药物的临床供药和商业供应。此外，公司在上海正在建设一个新的大型生产基地。\n\n和黄医药在中国复杂且不断发展的的医疗系统中拥有约20年的运营经验。公司组建了自有的肿瘤专科商业化团队，覆盖中国30个省市的2,100多家医院或癌症中心和逾两万名肿瘤科医生。此外，公司的合资企业共同组成了大规模、高效的药物营销及经销平台，拥有约3,600名销售人员。","中国（上海）自由贸易试验区蔡伦路720弄4号","91310115743282846Q","有限责任公司(港澳台法人独资)","SU WEI-GUO","2002-09-30","自由贸易试验区市场监督管理局","2002-09-30 至 2052-09-29","2025-03-17","44,200万(美元)","一般项目：医学研究和试验发展（除人体干细胞、基因诊断与治疗技术开发和应用）；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；企业总部管理。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）许可项目：药品委托生产；药品进出口；药品生产。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准）","www.hmplglobal.com","研究和试验发展","-",{"enterId":38,"enterName":18,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":25,"enterType":26,"enterLegalperson":27,"enterStablishdate":28,"regauthority":29,"licenseValidity":30,"approvaldate":31,"regcapital":32,"incapital":32,"businessscope":33,"ownBrand":5,"enterTelphone":13,"enterWebsite":34,"business":35,"performance":39,"socialSecurity":40,"registrationNumber":41,"enterQq":5,"enterMail":36,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"status":16,"regtrademark":5,"remark":5},"88934","开业","651人","310115400104835",{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"id":5,"brandId":5,"brandName":5,"busmodel":5,"franchiseFund":5,"totalStores":5,"devmodel":5,"franchiseIndustry":5,"investmenttel":5,"suitablePeople":5,"state":5},[],[],[46],{"createTime":47,"updateTime":48,"createBy":5,"updateBy":5,"industryId":49,"webId":5,"industryName":50,"industryAlias":5,"industryIcon":5,"industryTrans":51,"pageTitle":52,"pageDesc":53,"pageKeywords":54,"mainTitle":55,"pageSubtitle":56,"indSummary":57,"industryLevel":12,"parentId":58,"parentName":5,"sortOrder":59,"status":16,"classifyVisit":5,"totalVisits":60,"searchName":5,"starLevel":5,"limit":5},"2000-01-01 00:00:00","2026-06-16 16:50:00","10006","生物科技","\u002Fprofile\u002Fupload\u002F2023\u002F11\u002F08\u002F19f46e89d8cd077b73c7adb33bb2b59f.png","生物科技公司十大排行榜-国内知名生物科技公司有哪些-ZGALL品牌榜","2026年十大生物科技公司排行榜最新发布，生物科技公司十大排行榜前十名有中国生物、中国生物制药、百济神州、恒瑞、豪森药业、百利天恒、康方、复星医药、石药、信达。生物科技十大品牌排行榜由品牌研究部门收集整理大数据分析研究得出，帮助你了解中国生物科技公司有哪些。","生物科技公司排名前十有哪些,中国生物科技公司排名前十,生物科技有限公司排名,中国生物科技公司排名,全国生物科技公司排名","生物科技品牌排行榜","2026生物科技公司，生物制药公司排行榜，国内生物医药科技公司有哪些","生物科技哪个好？品牌TOP榜权威发布2026年生物科技名录；居前十的有：中国生物CNBG、中国生物制药、百济神州BeiGene、恒瑞医药、豪森药业、百利天恒、康方Akesobio、复星医药、石药CSPC、信达生物Innovent等，【行业品牌名录】基于大数据与人工智能技术，整合300+国际权威榜单及企业申报数据，通过算法分析市场占有率、创新力等12项指标，并解析超百万条舆情信息，采用加权模型（算法60%+专家30%+用户10%）生成动态排名。数据月度更新，申报需通过ISO认证审核，排名不分先后，仅供参考。",1411,99,589]